Strata Critical Medical Inc

Strata Critical Medical Inc(SRTA)の株式分析

$4.660

-0.049 (-1.06%)終値時点

Loading chart…
高値
4.680
始値
4.670
出来高加重平均価格
4.62
出来高
450.36K
時価総額
—
安値
4.530
売買代金
2.08M
EV/EBITDA(TTM)
-93.61

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its segments include Logistics and Clinical. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient.

stratacritical.com

AI分析 of Strata Critical Medical Inc (SRTA)

買い

Strata Critical Medical Inc (SRTA) is a good buy right now due to its recent strong earnings report showing a 15.1% sequential increase in clinical revenue for Q2 2026, reaching $24.3 million, and an upgraded EBITDA guidance of $33 million to $35 million for the year. The current price of $4.66 is attractive given the potential for significant upside, especially considering the projected trajectory based on similar historical patterns, which indicates a potential increase of 424.67%. However, investors should be cautious of the negative net income trend, with a reported loss of $10.5 million in Q2 2026, which poses a risk to profitability.

バリュエーション指標

Strata Critical Medical Inc(SRTA)の現在の予想PERは138.89で、5年平均は70.30です。

予想PER

適正
5年平均 P/E
70.30
現在のP/E
138.89
割高
149.36
割安
-8.76

予想EV/EBITDA

適正
5年平均 EV/EBITDA
90.84
現在のEV/EBITDA
-93.61
割高
349.26
割安
-167.58

予想PSR

適正
5年平均 P/S
1.41
現在のP/S
1.28
割高
1.64
割安
1.18

SRTA を保有するクジラ

T

Third Point LLC

+ を保有SRTA

-3.98%

3か月リターン

イベントタイムライン

2026-05-06 (ET)

07:40:00

Company Reports Q1 Revenue of $67.38M, Exceeding Expectations

07:40:00

Strata Adjusts FY26 EBITDA Guidance to $29M-$33M

2026-03-03 (ET)

07:10:00

Raises EBITDA Outlook to $29M-$33M

07:10:00

Will Heyburn: Company Aims for 30% Annual EBITDA Growth

2026-02-05 (ET)

08:50:00

Strata Critical Medical Enters $30M Credit Agreement with JPMorgan

ニュース

SRTA のよくある質問 — Alphio AI が回答

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its segments include Logistics and Clinical. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient. It operates in the Industrials sector.

Strata Critical Medical Inc (SRTA) is a good buy right now due to its recent strong earnings report showing a 15.1% sequential increase in clinical revenue for Q2 2026, reaching $24.3 million, and an upgraded EBITDA guidance of $33 million to $35 million for the year. The current price of $4.66 is attractive given the potential for significant upside, especially considering the projected trajectory based on similar historical patterns, which indicates a potential increase of 424.67%. However, investors should be cautious of the negative net income trend, with a reported loss of $10.5 million in Q2 2026, which poses a risk to profitability.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める